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Oxidative stress (OS) is thought to play an important role in the pharmacological and toxic effects of various drugs of abuse. Herein
we review the literature on the mechanisms responsible for the cardiovascular and hepatic toxicity of cocaine with special focus
on OS-related mechanisms. We also review the preclinical and clinical literature concerning the putative therapeutic effects of
OS modulators (such as N-acetylcysteine, superoxide dismutase mimetics, nitroxides and nitrones, NADPH oxidase inhibitors,
xanthine oxidase inhibitors, and mitochondriotropic antioxidants) for the treatment of cocaine toxicity. We conclude that available
OS modulators do not appear to have clinical efficacy.
1. Introduction
Oxidative stress (OS) can be defined as an unbalance between
the production of reactive oxygen and nitrogen species
(ROS and RNS) and the compensatory response of physio-
logical antioxidant mechanisms. The main ROS are super-
oxide (O
2
∙−), hydrogen peroxide (H
2
O
2
), hydroxyl (∙OH),
hydroperoxyl (HO
2
∙), peroxyl (RO
2
∙), alkoxyl (RO∙), singlet
oxygen (1O
2
), hypochlorous acid (HOCl), and ozone (O
3
)
while the main RNS are nitric oxide (∙NO), nitrogen diox-
ide (∙NO
2
), peroxynitrite (ONOO−), nitrous acid (HNO
2
),
dinitrogen tetroxide (N
2
O
4
), dinitrogen trioxide (N
2
O
3
), and
nitronium cation (NO2+). The most important sources of
ROS and RNS are represented by enzymatic reactions local-
ized in the mitochondria, the microsomes (cytochrome P450
enzymes), the cytosol such as xanthine oxidase (XO), and
the membrane-associated protein complex with its cytosolic
subunits NADPH oxidase (Nox). The production of ROS in
the phagocytes depends on the activity of peroxidases such as
myeloperoxidase and eosinophil peroxidase.
It has been suggested that OS plays an important role
in the physiopathology of various apparatuses and organs
including the cardiovascular system (ischemia and reperfu-
sion injury, heart failure, atherosclerosis, hypertension, etc.)
and the liver (acute and chronic damage) [1, 2]. There is also
evidence of significant involvement of OS in the pharmaco-
logical and toxic effects of drugs of abuse and particularly of
psychostimulants such as cocaine andmethamphetamine [3].
The level of OS in the aforementioned conditions can be
measured by a number of biomarkers, including H
2
O
2
, NO
derivatives (nitrite, nitrate, and S-nitrosothiols), isoprostanes
(deriving from the peroxidation of arachidonic acid), MDA
and other thiobarbituric acid reactive substances (TBARS),
4-hydroxynonenal (4-HNE), acrolein, thiol/disulfide ratio,
oxidation products of DNA (8-hydroxy-2-deoxyguanosine,
8-OH-G) and RNA (8-hydroxyguanosine, 8-OHD), and
nitrotyrosine. It is of note that, in several studies, cocaine-
induced OS was evaluated by the measurement of TBARS
[4–9] which is considered inferior to other methods for lipid
peroxidation like the evaluation of F2-isoprostanes [10].
In the present paper, we review the literature concerning
the cardiovascular and hepatic toxicity of cocainewith special
attention to the role of OS and the evidences about the
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possiblemodulators of OSwhich could have beneficial effects
in cocaine users.
2. Cardiovascular Toxicity of Cocaine
The earliest case reports of cardiovascular toxicity attributed
to cocaine date from the 1980s [11–13]. Cocaine abuse is asso-
ciated with both acute and chronic cardiovascular toxicity
[14–16], includingmyocardial ischemia [13, 17] and infarction
[18], arrhythmias [19], and cardiomyopathy [20–22]. Recent
epidemiological data indicate that cocaine is responsible for
a sizeable proportion of emergency department visits and
of sudden deaths [23, 24]. Data from 19 European countries
indicated more than 500 cocaine-related deaths in 2012 [25].
Approximately 5% to 10% of emergency department visits in
the United States have been attributed to cocaine-acute tox-
icity, chest pain being the most common symptom [15]. The
upward trend in cocaine-related chest pain and myocardial
infarction cases has induced the America Heart Association
to draft diagnostic and therapeutic guidelines [26]. Data
from the relative National Cardiovascular Data Registry
was recently published [27]. Histopathological studies have
shown that cocaine can precipitate myocardial ischemia in
the presence of coronary artery occlusion [28] as well as
of normal coronary arteries [29]. A recent review [23] of
49 cocaine-related deaths identified coronary atherosclerosis,
ventricular hypertrophy, cardiomegaly,myocarditis, and con-
traction band necrosis in almost a third of cases.
The pathogenesis bases of cocaine-induced cardiovascu-
lar toxicity [14, 30, 31] have been studied in detail [32, 33].
Cardiovascular cocaine toxicity can be related to its patho-
physiological effects on the sinoatrial node,myocardium, and
vasculature, including the coronary district.
2.1. Pathogenetic Mechanisms of the Cardiac Toxicity of
Cocaine. Cocaine can damage the heart through a variety
of mechanisms that have been elucidated only in part. In
the first place, cocaine has a direct cardiotoxic effect, due its
ability to block voltage-dependent K+ and Na++ channels in
the sinoatrial node and the myocardium, leading to reduced
contractility and to prolongation of the QT interval and the
QRS complex. It has been proposed that these two effects
may produce acute myocardial ischemia and infarction also
in absence of long-term cocaine abuse, of abnormalities in the
coronary arteries, and of other risk factors [34, 35].
Cocaine can exert its toxic effect on the heart also
indirectly, through the actions of catecholamines, and in
particular of norepinephrine. Indeed, cocaine is known
to block the reuptake of catecholamines by binding the
transporters for dopamine (DAT) and norepinephrine (NET)
[36]. Increased norepinephrine levels in the terminals of the
sympathetic nervous system lead to activation of adrenergic
receptors. Activation of 𝛽1 adrenergic receptors located on
the cells of the sinoatrial node and of the myocardium results
in increased heart rate and contractility. Activation of 𝛼1
receptors located on the smooth muscle cells of blood ves-
sels leads to vasoconstriction and increased blood pressure.
Increased heart rate, heart contractility, and blood pressure
may lead to an acute imbalance in oxygen supply/demand
[37, 38]. Oxygen deficiency can be further exacerbated by
the reduction in blood supply to myocardium produced
by 𝛼1-mediated constriction of coronary arteries [13]. In
turn, oxygen deficiency may lead to myocardial infarction.
Furthermore, the combination of the direct toxic effect of
cocaine and those of norepinephrine may lead to complex
arrhythmia [39].
In addition to producing oxygen imbalance, cate-
cholamines may damage the myocardium via at least three
additional pathogenetic mechanisms [30, 40]. First cate-
cholamines can promote cation translocation from the vas-
cular space to intracellular compartment [41] thus reducing
serum K+ [42] and Mg 2+ [43]. Concurrent hypokalaemia
and hypomagnesaemia may lead, given the pivotal role of
these cations in activity of the Na+/K+-ATPase pump [44], to
further cation dyshomeostasis, which in turn may contribute
to apoptosis and necrosis of cardiomyocytes. Moreover, this
mechanism [45], adding to the direct arrhythmogenic effects
of cocaine described above, may facilitate the development
of arrhythmias such as atrial fibrillation and ventricular
tachycardia.
A second pathway responsible for cardiotoxicity is
related, as first hypothesized by Fleckenstein and Coworkers
in 1974 [46], to catecholamines-induced calcium overload in
cytosol and mitochondria of cardiomyocytes [41]. Indeed,
stimulation of 𝛽-adrenergic receptors leads to activation of
protein kinase A (PKA) and increased Ca2+ levels in the
cytosol. This leads to phosphorylation of Ca2+-protein sub-
strates, including phospholamban, L-type calcium channel,
ryanodine receptor, cardiac troponin I, and myosin-binding
protein C [47, 48]. Increased cytosolic Ca2+ triggers the
release of Ca2+ in the mitochondria. The mitochondrial role
in physiological intracellular Ca2+ homeostasis as well as
in necrosis and apoptosis signaling is well demonstrated
[49]. Mitochondrial Ca2+ overload impairs respiration and
ATP production and produces change in permeability of the
mitochondrial membrane (eventually leading to its rupture),
which represents critical events for the further structural
degeneration of cardiomyocytes [50].
Moreover Ca2+ overload (as well as ROS mitochondrial
production, see below) is responsible for themassive opening
of mitochondria Permeability Transition Pores (mPTP) [51]
resulting in further dysfunctional and structural degenera-
tion of these organelles.
An indirect cardiotoxic effect of catecholamines
may derive from action of their oxidation products, the
aminochromes. Notably, excessive level of circulating
catecholamines (and consequent saturation of the
monoaminooxidase and catechol-o-methyl transferase
systems)may cause the increased formation of adrenochrome
(obtained by oxidation of adrenaline) [40, 52] of 5,6-
dihydroxy-1-methylindole and of adrenochrome alkaline
rearrangement product adrenolutin. In the heart the
enzyme cytochrome c oxidase has been associated with
adrenochrome formation [52].
Experimental studies investigating the relationship
between aminochromes and cardiotoxicity [52, 53]
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demonstrated a direct toxic effect on cardiomyocytes:
disturbances in cellular Ca2+ homeostasis and a perturbation
of oxidative phosphorylation have been reported.
Accordingly, increased levels of adrenolutin were observed in
death-associated heart failure [54].Moreover, aminochromes
are known to induce redox cycling with consequent
generation of ROS (see below).
More recently, OS and generation of ROS have been iden-
tified as one of the most important mechanisms of cocaine-
induced cardiomyocyte toxicity [6, 30, 31, 55, 56]. Increased
expression iNOS and decreased levels of myocardial SOD
and catalase were found in the cardiomyocytes of patients
with dilated cardiomyopathy related to chronic cocaine abuse
[20]. Indeed, ROS formation has been thought to be related
to cocaine-induced catecholamine release [56]: 𝛼
1
and 𝛽
receptors stimulation, as well as enzymatic and nonenzymatic
degradation of catecholamines, lead to intracellular ROS
formation.
2.1.1. 𝛼
1
-Adrenoceptors Stimulation and Production of ROS.
In the plasma membranes of cardiac cells, 𝛼
1
-adrenoceptors
stimulation increases the activation of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidases [57], an electron
donor which in turn produces the superoxide anion radical
O
2
∙− formation [56, 58]. The role of NADPH-driven super-
oxide production in cocaine induced cardiac dysfunction is
well recognized [59]. Indeed, the family of Nox enzymes is
considered the major sources of ROS in the cardiovascular
system [58, 60]: the proteins of the Nox family produce O
2
∙−
by transferring an electron from NADPH (or NADH) to O
2
.
It is believed that Nox1, Nox2, andNox4 are expressed signifi-
cantly in the vascular system [61, 62] while experimental data
in cardiomyocytes had demonstrated that the Nox subunit
Nox1, but notNox2 orNox4, is implicated in norepinephrine-
induced Nox-generated ROS [63]. Inhibition of Nox activity
by apocynin prevented the increase in ROS production
and cardiac dysfunction induced by chronic administration
of cocaine in vivo in rats [64]. Moreover, Nox activity is
associated with other ROS-inducing enzymatic sources such
as xanthine oxidoreductase (XOR): a fundamental role of XO
was confirmed in an in vivo experimental model of cocaine-
induced diastolic dysfunction [65], in which treatment with
XO-inhibitor allopurinol prevented the cocaine-increase in
mitochondrial ROS levels.
2.1.2. 𝛽-Adrenergic Receptors Stimulation and Production
of ROS. As discussed above, 𝛽-adrenergic receptors (𝛽-
AR) stimulation activates a GTP-binding protein S, which
stimulates adenylyl cyclase (AC) to produce cAMP, which
in turn activates PKA. It has been demonstrated that 𝛽-
AR stimulation may contribute to mitochondrial ROS pro-
duction in cardiomyocytes: indeed the 𝛽-adrenergic ago-
nist isoproterenol (ISO) increased, in a concentration- and
cAMP-protein kinase A-dependent manner, mitochondrial
O
2
∙− production in freshly isolated mouse cardiomyocytes
and induced a twofold increase of MDA protein adducts
relative to controls in perfused hearts [66]. Accordingly,
in vivo administration of mitochondria-targeted antioxidant
MitoQ had shown to prevent left ventricular (LV) diastolic
dysfunction (characterized by an increase in the index of LV
relaxation, in LV end-diastolic pressure-volume relation, and
in LV end-diastolic pressure) induced in rats treated with
cocaine for 7 days [67]. Beta-AR stimulation induced both
cAMP [68] and PKA increase both in bovine [69] and in rat
[68, 70] cardiomyocytes mitochondria.
Experimental data in mouse cardiomyocytes [66] have
demonstrated that 𝛽-AR exposure to agonist ISO leads to an
increase in ROS, suggesting ROS production as a direct con-
sequence of activation of the cAMP-PKA signaling pathway
in mitochondria. Importantly, the increase in mitochondrial
ROS production appeared to be Ca2+-independent, since a
selective increase of the amplitude of Ca2+ transient did not
increase ROS production [66].
𝛽-AR stimulation is also implicated in the impairment of
antioxidant system. Indeed, significant reduction in CuZn-
SOD enzyme activity has been found in hearts from ISO-
treated rats as well as in ISO-stimulated isolated cardiomy-
ocytes [71]. Moreover, a reduction in manganese-SOD (Mn-
SOD) expression induced by chronic ISO was more recently
found in type 5 AC (1 of 2 major AC isoforms in heart)
transgenic mice [72].
2.1.3. OS from Catecholamines Metabolites
(Aminochromanes). As mentioned above, when the
enzymatic catabolism of catecholamines is not sufficient, they
can undergo chemical oxidation causing additional OS [40].
The implication of aminochromanes in the pathogenesis of
cardiac diseases [53, 73] is also well recognized.
Formation of superoxide anion O
2
∙− (due to an oxida-
tion pathway that involves the formation of highly reactive
intermediaries o-semiquinones and o-quinones) [74] has
been observed in both in vivo [75] and in vitro models [74,
76]. The superoxide anion O
2
∙− can cause the oxidation of
epinephrine [52, 77, 78] and of metal ions copper [79] and
iron [77], enhancing the oxidation of catecholamines. Thus,
iron chelation can protect against the cardiotoxicity induced
by the metabolites of catecholamines: an in vitro study in rat
ventricular cardiomyoblast assessing the potential cardiopro-
tective effects of some chelating agents had suggested further
investigation in vivo animal models [80].
Catecholamines metabolites can also reduce antioxidant
defences by decreasing the levels of reduced glutathione
(GSH) and increasing the oxidized glutathione (GSSG) con-
tent as observed in adrenaline-treated isolated rat cardiomy-
ocytes [74, 79].
2.2. Pathogenetic Mechanisms of Cocaine Vascular Toxicity
2.2.1. Cocaine Effect on Vascular Smooth Muscle Cells.
Cocaine sympathomimetic activity and consequent agonist
action at 𝛼
1
adrenergic receptors (𝛼
1
-AR) in vascular smooth
muscle cells cause contraction in the vascular system. The
activation of these receptors leads in fact to the formation of
inositol triphosphate and diacylglycerol (via phospholipase
C), which in turn cause an increase in Ca2+ entry and in
release from Ca2+ stores in smooth muscle cells [81]. Despite
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the different contribution of each 𝛼
1
-AR subtype [82, 83] in
the regulation of contraction in different vascular districts,
the net result of 𝛼
1
-AR stimulation is represented by an acute
increase in blood pressure.
2.2.2. Cocaine Effect on Endothelial Cells. A further contribu-
tion in the pathogenesis of cocaine-induced vasoconstriction
is due to its acute and chronic effect on endothelial cells func-
tion [84]. An impairment in endothelium-dependent vasore-
laxation, assessed as a decrease in forearm blood flow in
response to intraarterial acetylcholine and nitroprusside, was
found in long-term users of cocaine [85]. Accordingly exper-
imental studies [86, 87] demonstrated a cocaine-induced
endothelial dysfunction with a decrease in NO release and
in the constitutive enzyme NO-synthase (eNOS) content, as
well as an increase in endothelin-1 (ET-1) production and ET-
1 receptor type-A (ETAR) protein expression [84]. Increased
number of circulating endothelial cells (CECs) indicat-
ing endothelial dysfunction was recently demonstrated in
cocaine abusers [88]. Furthermore, enhancement of cocaine-
induced vasoconstriction was observed after N(G)-nitro-L-
arginine methyl ester-induced inhibition of NO synthesis in
vitro [89].
Concomitant decrease in NO-induced vasodilatation
and ET-1-induced vasoconstriction may enhance 𝛼
1
-AR-
mediated vasoconstriction. It has been suggested that inhibi-
tion of eNOS expressionmay partially derive from high levels
of ET-1 through a PKC-mediated pathway in endothelial
cells [90] and/or through ET-1 receptor type-A (ETAR)
stimulation, which in turn can increase ROS production [91,
92].
Chronic cocaine exposure and consequent endothelial
dysfunction may precipitate early atherosclerosis [93] and
the persistence of endothelial cell damage beyond its acute
effect on the blood vessels can further increase cardiovascular
risk in cocaine abusers [88, 94]. Since that ET-1 increase
was significantly associated with atherosclerotic lesion [95], it
may be argued that it plays a fundamental role in the cocaine-
induced vasoconstriction at sites of significant stenosis [96].
Although discrepant results were also reported [97],
probably due to methodological differences, there is some
evidence indicating that cocaine may exert an inhibitory
effect on the production of prostacyclin (PGI
2
) by endothelial
cells [98, 99]. Since the release of both vasodilatatory PGI
2
and NO may result from stimulation of ET-1 receptor type-
B
1
(ETB
1
) receptors on endothelial cells, it is possible that
the inhibitory effect of cocaine on NO release also extends
to PGI
2
release [100].
Another important factor that can contribute to cocaine
prothrombotic action is its direct action on endothelial cells
secretion of vonWillebrand factor (VWF). Indeed, a recent in
vitro study [101] demonstrated that cocaine and its metabo-
lites induced VWF secretion in a concentration-dependent
manner from three endothelial cell types (human umbilical
vein, brain microvasculature coronary artery endothelial
cells).
2.2.3. Cocaine Effect on Platelet Function. Whereas both
experimental and clinical data agree on the fact that cocaine
can affect endothelial function, leading to vasoconstriction,
there is conflicting evidence about the direct effect of cocaine
on platelets. Increased platelet activation was observed in
vitro in rabbit platelet-rich plasma (PRP), preincubated with
cocaine hydrochloride [102] as well as in vivo in dogs treated
with intravenous cocaine [103]. The findings obtained with
human platelets in vitro are less consistent. At concentrations
comparable to the systemic concentrations produced by
lethal doses, cocaine decreased platelet aggregation induced
by agonists in PRP obtained from healthy human subjects
[104]. In contrast, two in vitro studies conducted with cocaine
concentrations comparable to the systemic concentrations
associated with the “high” showed increased platelet activa-
tion in whole blood preparations [105, 106], whereas other
studies found no effect of cocaine [107]. Finally, increased
platelet expression of surface P-selectin was found in blood
samples from chronic cocaine users [107]. It is possible
that these discrepancies were due to differences in substrate
(animal versus human platelets), in model (in vitro versus in
vivo), in methodology (whole blood versus PRP), and in the
concentrations of cocaine used.
In vivo studies in healthy subjects [108] and in chronic
cocaine user [109], although not univocally [110], gave evi-
dence of activation of platelets, assessed by increase of P-
selectin expression [109] and of soluble CD40L, a transmem-
brane molecule mainly expressed by activated platelets [111].
Due to physiological interaction of platelets with vascular
endothelium and circulating blood cells such leukocytes, it
may be argued that an indirect, rather than a direct, mecha-
nism of action is involved in the cocaine platelets activation.
Indeed, the above mentioned cocaine-induced vasospasm,
consequent increase in shear stress, and endothelial dys-
function may induce a platelet activation, as demonstrated
by release of constituents of their 𝛼-granules [106] and of
thromboxane A2 [99]. A further contribution may derive
from VWF interaction with the platelet receptor GPIb and
their subsequent activation [108].
2.2.4. OS and Cocaine-Induced Endothelial Toxicity. Besides
cardiomyocytes, also endothelial cells (ECs)may releaseROS,
mainly due to its presence of enzymes such as XO, NOS,
mitochondrial MAO, and NAPDH oxidase. Some data in
literature indicate a direct or an indirect cocaine action
on endothelial cells, both on enzymes expression and on
mitochondrial function.
2.2.5. XOandProduction of ROS. In bovine aortic endothelial
cells, it has been observed that shear stress induced an
enhancement of xanthine-dependent O
2
∙− production [112],
associated with a decrease in xanthine dehydrogenase (XDH)
protein. Furthermore, inhibition of the Nox decreased XO
levels and prevented the increase of O
2
∙−, highlighting the
central role of Nox in modulating endothelial production
of ROS. It may be suggested that vasoconstriction effect
of cocaine and consequent blood shear stress may trigger
endothelial ROS production via Nox/XO enzyme.
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In agreement with this hypothesis, cocaine-induced car-
diac dysfunction (alteration of cardiac output and stroke
volume) was found to be associated with increased Nox
and XOR activity in vivo study in rats [64]. Furthermore,
apocynin or allopurinol treatment inhibited the cocaine-
induced cardiac alteration and the myocardial production
of O
2
∙− confirming the role that Nox-derived ROS play in
modulating ROS production by XO [64].
2.2.6. Nitric Oxide Synthase and Production of ROS. As
mentioned above, cocaine-induced decrease in endothelial
NO release and in the constitutive enzyme eNOS content
has been observed [84]. A contribution to this cocaine
endothelial toxic effect may derive from its increasing action
in Nox, which in turn (besides the increase in O
2
∙−) may
induce oxidation of tetrahydrobiopterin, a cofactor of NO
synthase: as a consequence eNOS uncoupling leads to the
observed reduction in NO synthesis and to an enhancement
in O
2
∙− [113].
2.2.7. ROS in Endothelial Mitochondria. Besides the well-
recognized energy-producing activity, notably mitochondria
are the major source of cellular reactive oxygen [114] both
in cardiomyocytes and in EC [40, 115]. An important role
of endothelial mitochondria in pathogenesis of endothelial
dysfunction is due to their role in signaling cellular responses,
among which the production of ROS [116].
2.2.8. Mitochondrial Monoaminooxidase and Production
of ROS. Among the sources of mitochondrial ROS, the
monoamine oxidase (MAO) family, located to the outermito-
chondrial membrane, causing the oxidative deamination of
catecholamines, results in hydrogen peroxide (H
2
O
2
) forma-
tion [117]. Accordingly, experimental data in literature indi-
cate an increase in H
2
O
2
cardiac production after the sympa-
thomimetic drug amphetamine administration [118]. In this
regard a recent in vitro study has demonstrated in human
pulmonary EC [119] exposed to cocaine a significant increase
in H
2
O
2
production; due to the modulating action of H
2
O
2
on endothelium functions such as endothelium-dependent
vasorelaxation, apoptosis, and remodeling [120] it may be
argued that cocaine-induced increase in catecholamines and
in the consequent MAO-mediated H
2
O
2
production in
endothelial mitochondria could further enhance endothelial
dysfunction, contributing to cocaine toxic effects on vascular
district.
An important contribution to OS may derive from the
process, namely, ROS-induced ROS release (RIRR) [120]: this
process makes a significant amplification to ROS production
[121]. Briefly, OS in themitochondriamay trigger the opening
of mitochondrial transition pore that leads to a further
increase in ROS generation. RIRR phenomena have been
recognized in both physiological (promoting an elevation in
the cell tolerance to OS, until the destruction of impaired-
function mitochondria) [122] and pathological conditions
such as cardiac ischemia-reperfusion [123] associated with
acute myocardial infarction.
2.2.9. ROS Production by Mitochondrial Nox4. Another
possible source of ROS in endothelial mitochondria is Nox4
[124], generating a higher hydrogen peroxide to superoxide
ratio than Nox1 and Nox2. Nox4 involvement in endothelial
cells process and in responses to hypoxia and OS is well
recognized [125]; moreover it has been demonstrated that
the expression or activity of Nox4 is increased in response
to the proinflammatory mediators TNF-𝛼 [126]. While a
cocaine-induced increase in Nox has been demonstrated in
cardiac tissue [64], to date no data in literature are present
on the effects of cocaine on Nox at endothelial level. An
indirect effect of cocaine activation of Nox may derive from
the cocaine induction of the TNF-𝛼 expression, observed in
bovine aortic endothelial cells [127].Moreover a Nox increase
and the consequent endothelial superoxide production were
also found in bovine aortic endothelial cells exposed to
oscillatory shear stress [112].
3. Cocaine Hepatotoxicity
Cocaine abuse is known to induce acute [128–132] and
chronic [130, 131, 133] liver toxicity. Clinical manifestations
of cocaine-induced hepatic damage range from elevation of
liver enzyme levels in chronic users [131, 133, 134] to acute liver
failure associated with hepatitis [128], to fulminant liver fail-
ure associatedwith acute rhabdomyolysis [132] or thrombotic
microangiopathy [128]. Histopathological examination has
shownmidzonal [132] and periportal [130] necrosis, as well as
steatosis in the surviving hepatocytes [131]. The involvement
of OS in cocaine liver toxicity has been reviewed recently
[135, 136].
In vivo animal studies suggest the involvement of cocaine
metabolites in the genesis of hepatotoxicity. Experiments
conducted in rats [137] and mice [138, 139] have shown
that cocaine-induced hepatotoxicity is at least partly depen-
dent on cocaine N-demethylated metabolites norcocaine
(NCOC), and N-hydroxynorcocaine (N-OH-NCOC) and
norcocaine nitroxide (NCOC-NO.) [139, 140]. Inhibition of
cytochrome P-450 (CYP450) mediated activation of cocaine
metabolism produced a significant inhibition of hepatotoxic-
ity in mice in vivo [138] and ex vivo in liver microsomes [141],
while in vivo induction of CYP450 activity enhanced the
cocaine hepatotoxicity [142]. Studies in mice demonstrated
that cocaine reduces GSH levels in the liver [143, 144] and that
depletion of intracellular GSH concentrations exacerbated
cocaine hepatotoxicity [144]. Finally, it has been shown
that pretreatment with the GSH precursor NAC exerted a
protective effect against cocaine hepatotoxicity in mice [145],
while pretreatment with endotoxin lipopolysaccharide (LPS)
led inKuppfer cells to the formation ofNOwhich exacerbated
cocaine toxicity [146].
Given that the synthesis of both NCOC-NO and GSH
requires the presence of the cofactor NADPH, it has been
hypothesized that a decrease in hepatocytes NADPH content
and consequent impairment of antioxidant system may con-
tribute to enhance OS [147].
The ability of cocaine to deplete intracellular GSH may
also depend on the effects of its N-oxidative metabolites on
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themitochondrial function of the hepatocytes. In vivo studies
in rats [148, 149] have shown that these metabolites can
decrease GSH levels and membrane potential and increase
ROS production in the mitochondria [9]. Mitochondrial
generation of ROS has been shown also in isolated mouse
liver mitochondria treated with NCOC, N-OH-NCOC, and
NCOC-NO but not with cocaine [150], confirming the
fundamental role of the N-oxidative metabolites of cocaine
in OS-mediated hepatotoxicity.
Ex vivo and in vitro studies have confirmed the in vivo
data. Cocaine-induced GSH depletion and GSSG production
were observed in cultures of mouse and, to a lesser extent,
in rat cocaine-treated hepatocytes [151, 152] with mouse
being more sensitive to cocaine hepatotoxicity, as observed
in cultured liver slices from different species [153]. In primary
cultures of rat hepatocytes treated with the CYP-450 inducer
phenobarbital, it has been observed that cocaine-induced
alteration in the thiol redox equilibrium may be crucial for
the development of hepatocyte toxicity and consequent LDH
release [154].Moreover cocaine-treated hepatocytes had been
associated with decrease in catalase and Mn-SOD [155].
Further confirmation of implication of OS is derived from rat
hepatocyte model of cocaine cytotoxicity in which a partial
prevention of cytotoxicity byNAC [156] and by deferoxamine
(a ferric iron chelator) was observed [152, 156].
In summary, human and experimental data provide
evidence of direct toxic effects of cocaine on the hepatocytes.
This hepatotoxicity appears to be dependent mainly on N-
oxidative metabolites of cocaine. Impairment of the antiox-
idant system as depletion of intracellular and mitochondrial
GSH also contributes to cocaine hepatotoxicity.
4. Potential Therapeutic Effects of OS
Modulators in Cocaine Abuse
Antioxidants or modulators of OS as they are often referred
to due to their possible prooxidant activity can be classified in
low (LMW) and high (HMW) molecular weight and further
subdivided into endogenous or exogenous. The exogenous
ones can be natural or synthetic [2]. Several evidences
indicate that some of these compounds could have beneficial
effects on cocaine-induced toxic effects.
4.1. NAC. NAC has been used for many years in the treat-
ment of acute paracetamol intoxication, as a mucolytic for
chronic obstructive pulmonary disease and as a protec-
tant in contrast-induced nephropathy. NAC can scavenge
directly ROS and particularly the hydroxyl radical ∙OH and
hypochlorous acid but due to its high first pass metabolism
and low bioavailability acts mainly as a precursor of GSH
in many organs, including the liver [145] and the brain
[157]. Asmentioned before,mice pretreatment withNAChad
a protective effect against cocaine-mediated hepatotoxicity
[146]. Importantly, NAC treatments appear to be safe and
tolerable both in preclinical and in clinical studies [158, 159].
GSH is a very important endogenous antioxidant in the
brain and it has been known for a long time that its level
decreases in neuropsychiatric disorders such as depression,
schizophrenia, and bipolar disorder [160] and is currently
considered a promising drug for these pathological condi-
tions [158, 160]. A recent double-blind placebo-controlled
trial failed to demonstrate that NAC reduces cocaine use in
cocaine-dependent subjects but showed some evidence that it
can prevent relapse in individuals who had already achieved
abstinence from cocaine [161]. Thus NAC may be useful as
a relapse prevention agent in abstinent cocaine-dependent
subjects [161].
The mechanism of action of NAC in the aforementioned
conditions is complex and not completely elucidated. The
main activities contributing to its efficacy seem to be related
to (i) its capability of providing cysteine which is the limiting
amino acid in GSH production; (ii) the exchange of extracel-
lular cysteine provided by NAC with intracellular glutamate
by the cysteine/glutamate transporter causing the activation
of presynaptic mGluR2/3 receptors which inhibit glutamater-
gic neurotransmission and excitotoxicity [162, 163]; (iii) direct
antioxidant activity related to its capability of scavenging rad-
icals such as hydroxyl and peroxynitrite [164]; (iv) induction
of the expression of antioxidant enzymes through the nuclear
E2-related factor (Nrf2)/ARE system [165]. It is of note
that the Nrf2 pathway represents a promising therapeutic
approach to restore the redox balance in the CNS and in other
organs and that only a few Nrf2-activating compounds have
been tested in a clinical setting until now [166].
4.2. SOD Mimetics. SOD is a very important antioxidant
enzyme in mammals existing in three different physiological
forms: MnSOD in the mitochondrial matrix, CuZnSOD in
the cytoplasm, and CuZnSOD in extracellular fluids [167].
Given the central role of the superoxide radical in oxidative
pathological phenomena, different drugs with SOD activity
were developed [168].
An infusible formof humanmanganese SOD (rMn-SOD)
as new therapeutic option capable of crossing cell membranes
was recently proposed for dilated cardiomyopathy caused by
cocaine [20].
4.3. Nitroxides andNitrones. Most antioxidants acting as spin
traps have a nitroxide or nitrone nucleus.
Nitroxides are nonmetal catalytic antioxidants. One
of the most common is Tempol (4-hydroxy-2,2,6,6-
tetramethylpiperidine-N-oxyl) with SOD and catalase
enzymatic activities which can be administered orally
and can cross biological membranes and react with ROS
intracellularly and within mitochondria [169].
Nitrones are potent antioxidants capable of forming
stable nitroxyl radicals when reacting with oxygen radi-
cals. Several nitrones, including 𝛼-phenyl-tert-butylnitrone
(PBN), have been shown to have neuroprotective properties
in experimental animal models of stroke, Parkinson’s and
Alzheimer’s disease [170], as well as in preclinical models
of CNS injury [171]. Treatment with Tempol can attenuate
OS in the prefrontal cortex and in the nucleus accumbens
[172] and inhibited cocaine self-administration in vivo in rats,
suggesting that reinforcing effects of cocaine are mediated, at
least in part, by ROS [173].
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To the best of our knowledge, no data are present in
literature on efficacy of nitroxides and nitrones on cocaine-
induced cardiac or hepatic injury.
4.4. Nox Inhibitors. As mentioned above, Nox are among
the best characterized sources of superoxide and the pre-
dominant ROS producing enzymes in the vascular smooth
muscle cells, in the myocardium, and in blood vessels [174].
Hypertension, atherosclerosis, hyperlipidemia, and diabetes
are associated with endothelial dysfunction probably medi-
ated by Nox driven production of ROS [175]. Compared to
radical scavengers, Nox inhibitors could be more effective
because they are able to block the formation of ROS at the
source [176].
Several Nox inhibitors are currently available, includ-
ing apocynin, which is an orally active natural compound
obtained from the roots of Picrorhiza kurroa capable of
inhibiting Nox activation probably by preventing the assem-
bly of Nox2 with p47phox [177, 178].
Importantly it was reported that apocynin can prevent
cocaine-induced myocardial damage in rats [64] providing a
good evidence for the therapeutic potential of Nox inhibitors
in the treatment of cocaine cardiotoxicity [179].
4.5. XO Inhibitors. Allopurinol is a well-known inhibitor of
XO used for decades for the treatment of gout [180]. It can
prevent OS by inhibiting XO and also by scavenging directly
hydroxyl free radicals.
Clinical studies showed that allopurinol has beneficial
effects in chronic kidney disease patients [181]. XO inhibition
by allopurinol (or the active metabolite oxypurinol) could
be beneficial in hyperuricemic patients with congestive heart
failure [182]. Unfortunately, allopurinol is not devoid of side
effects such as severe skin reactions and renal impairment
[182].
Allopurinol and 1,3-dimethylthiourea, a scavenger of
hydroxyl radical, produced a potent inhibition of hepatotox-
icity induced by cocaine in adult male mice [183].
Apocynin or allopurinol prevented cocaine-induced car-
diac alteration by restoration of cardiac output, stroke vol-
ume, and fractional shortening, associated with a reduction
of the myocardial production of superoxide anions and an
enhancement of catalase activity [55] suggesting thatNADPH
andXO can act synergically to formmyocardial ROS and that
their inhibition could prevent the onset and progression of
cocaine-induced left ventricular dysfunction [55].
4.6. Mitochondriotropic Antioxidants. Cationic
triphenylphosphonium (TPP) derivatives such as MitoQ
have high affinity for the innermitochondrial membrane that
is negatively charged. They can cross the blood-brain barrier
even if the uptake in the brain appears less than for other
organs [184]; TPP compounds can be administered orally
and did not raise safety concerns so far [184]. MitoQ was
protective in a large number of cell models of mitochondrial
OS and has been shown to be well tolerated, orally active,
and safe in humans [185].
Cocaine can be toxic for mitochondria, causing for-
mation of ROS, impaired electron transfer, suppression of
ATP production, membrane permeabilization with release of
cytochrome C, and subsequent cell death: MitoQ can prevent
these abnormalities protecting against cardiac dysfunction
[67].
Preparation of small cell-permeable peptides (SS-
peptides) which accumulate in the mitochondria and bind to
the inner membrane thanks to the presence of basic amino
acids positively charged at physiological pH had shown to
protect mitochondria against oxidative damage [185, 186].
The use of these peptides to deliver antioxidant molecules
into mitochondria and provide protection against cocaine
induced OS has been proposed [187].
4.7. Deferoxamine. NAC and deferoxamine (DFO, an iron
chelating agent that prevents ROS generation by inhibit-
ing the Fenton reaction) protected rat hepatocytes in cul-
ture against the OS induced by cocaine, confirming the
involvement of oxygen radicals in cocaine-induced necro-
sis/apoptosis [188]: hepatocytes were preincubated for 24 h
either in the presence or in the absence of NAC or DFO
and exposed for another 24 h to increasing concentrations of
cocaine together with NAC or DFO. Pretreatment with defer-
oxamine complex with iron ion (III), aminoguanidine, and
N-methyl-d-glucamine dithiocarbamate complex with iron
ion (II) produced a marked inhibition of the hepatotoxicity
induced by a single administration of cocaine, as indicated
by histopathological examination, alanine aminotransferase
activity, and nitrite/nitrate levels [183].
4.8. Selenium. In rats, pretreatment for 4 weeks with sele-
nium reversed both the OS and the contractile dysfunction
induced by repeated (7 days) cocaine administration in rats
[189]: cardiac function was evaluated by cardiac index and
left ventricular fractional shortening measured by echocar-
diography.
4.9. Minocycline. Minocycline, a second generation tetracy-
cline, has been found in rats to prevent cardiac myocyte
death (associated with an increase in OS evidenced by
low GSH/GSSG ratio and increased levels of 4-hydroxy-2-
nonenal) induced by prenatal cocaine exposure [190].
4.10. Auranofin. Pretreatment ofmice with auranofin (a well-
known disease-modifying gold compound used for rheuma-
toid arthritis recently proposed also for other therapeutic
applications) [191] showed an interesting protective effect
against hepatic injury caused by cocaine by inducing over-
expression of heme oxygenase-1 (HO-1), an important OS
marker responsible for heme degradation [192]. Unfortu-
nately, auranofin is not devoid of toxic effects [193] but this
result indicates that it could be worthwhile to search for less
toxic inhibitors of HO-1 to reduce hepatic injury induced by
cocaine.
4.11. Amiodarone. Amiodarone is a class III antiarrhythmic
drug used in heart failure and postischemic heart capable
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of protecting cardiac myocytes against OS [194]. However,
amiodarone pretreatment did not affect the seizure incidence
or mortality in mice treated with high doses of cocaine [195].
The efficacy of amiodarone in the treatment of cocaine-
induced dysrhythmias is still undefined [196] and further
studies should be performed on this and other antiarrhyth-
mic drugs.
4.12. Trolox. Trolox, a hydrophilic analog of vitamin E with
well-known antioxidant properties [197], was found to reduce
the production of ROS induced by exposure to cocaine and
the neurotoxic effect of the HIV-1 transactivating protein Tat
[198].
5. Conclusion
In the present paper, several studies were reported demon-
strating the important role of OS in the activity and toxicity
of cocaine with special attention to its cardiovascular and
hepatic effects. Several evidences were reported showing the
potential beneficial effects of antioxidants or modulators
of OS (as they are referred to considering their possible
prooxidant effects in certain conditions) even if it should be
kept in mind that, like in the case of NAC, their mechanism
of action, which is often complex and not always fully
elucidated, is not only related to their antioxidant activity.
Unfortunately, for most of these modulators of OS the
preclinical and clinical studies are limited and do not allow
drawing definitive conclusions on their efficacy in relation to
cocaine toxicity. Even in the case ofNAC limited clinical trials
were performed in cocaine users and the biomarkers of OS
were not considered with sufficient attention.
Other studies should then be performed also considering
the difficulty to demonstrate the clinical efficacy of modu-
lators of OS. In fact, several clinical trials on antioxidants
in pathological events such as neurodegenerative, cardio-
vascular, or pulmonary diseases, conditions associated with
ischemia and reperfusion injury, chronic kidney disease, or
psychiatric disorders failed in the last few years for different
possible reasons including [1, 2]:
(1) In physiological conditions, OS is controlled by a
complex mixture of endogenous and exogenous antioxidants
(lipophylic or hydrophilic, enzymatic or nonenzymatic) and
when used therapeutically one single antioxidant may not be
sufficient. The challenge is then to design trials with the right
mixtures of substances at the right doses.
(2) Certain conditions probably require the delivery of
higher amounts of antioxidants to specific organs or tissues
or organelles such as the mitochondria.
(3) The dose and/or duration and/or regimen and/or
timing of the treatment should be appropriate.
(4) Some antioxidants may have prophylactic activity but
not be very effective after the onset of the condition. If the
stage of the disease is too advanced, patients will not probably
receive benefit from the therapy.
(5)Most clinical trials were performed without a proper
selection of the patients based on validated biomarkers of
oxidative stress. Furthermore, whole body OS markers may
not be appropriate for specific diseases in which OS involves
specific tissues or organs or organelles.
(6) Some antioxidants can act as prooxidants in certain
conditions or have adverse side effects.
In conclusion the effect of modulators of OS on the
activity and toxicity of cocaine should be further studied in
order to develop new drugs useful for the treatment of OS-
mediated cocaine toxic effects.
Abbreviations
CNS: Central nervous system
GSH: Glutathione
HO: Heme oxygenase
MDA: Malondialdehyde
NAC: N-Acetylcysteine
Nox: NADPH oxidase
NO: Nitric oxide
OS: Oxidative stress
RNS: Reactive nitrogen species
ROS: Reactive oxygen species
SOD: Superoxide dismutase
XO: Xanthine oxidase.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
References
[1] O. Firuzi, R. Miri, M. Tavakkoli, and L. Saso, “Antioxidant
therapy: current status and future prospects,”CurrentMedicinal
Chemistry, vol. 18, no. 25, pp. 3871–3888, 2011.
[2] L. Saso and O. Firuzi, “Pharmacological applications of antioxi-
dants: lights and shadows,” Current Drug Targets, vol. 15, no. 13,
pp. 1177–1199, 2014.
[3] J. D. Uys, P. J. Mulholland, and D. M. Townsend, “Glutathione
and redox signaling in substance abuse,” Biomedicine & Phar-
macotherapy, vol. 68, no. 6, pp. 799–807, 2014.
[4] A. O. Sordi, F. Pechansky, F. H. P. Kessler et al., “Oxidative stress
and BDNF as possible markers for the severity of crack cocaine
use in early withdrawal,” Psychopharmacology, vol. 231, no. 20,
pp. 4031–4039, 2014.
[5] C. T. D. Antoniazzi, N. Boufleur, C. S. Pase et al., “Tactile stimu-
lation andneonatal isolation affect behavior and oxidative status
linked to cocaine administration in young rats,” Behavioural
Processes, vol. 103, pp. 297–305, 2014.
[6] T. Cunha-Oliveira, L. Silva, A. M. Silva, A. J. Moreno, C. R.
Oliveira, and M. S. Santos, “Acute effects of cocaine, morphine
and their combination on bioenergetic function and suscepti-
bility to oxidative stress of rat liver mitochondria,” Life Sciences,
vol. 92, no. 24–26, pp. 1157–1164, 2013.
[7] V. Bashkatova, J. Meunier, A. Vanin, and T. Maurice, “Nitric
oxide and oxidative stress in the brain of rats exposed in utero to
cocaine,” Annals of the New York Academy of Sciences, vol. 1074,
pp. 632–642, 2006.
[8] V. Bashkatova, J. Meunier, T. Maurice, and A. Vanin, “Memory
impairments and oxidative stress in the hippocampus of in-
utero cocaine-exposed rats,” NeuroReport, vol. 16, no. 11, pp.
Oxidative Medicine and Cellular Longevity 9
1217–1221, 2005.
[9] B. G. Devi and A. W. K. Chan, “Cocaine-induced peroxidative
stress in rat liver: antioxidant enzymes and mitochondria,”
Journal of Pharmacology and Experimental Therapeutics, vol.
279, no. 1, pp. 359–366, 1996.
[10] K. Moore and L. J. Roberts II, “Measurement of lipid peroxida-
tion,” Free Radical Research, vol. 28, no. 6, pp. 659–671, 1998.
[11] D. L. Coleman, T. F. Ross, and J. L. Naughton, “Myocardial
ischemia and infarction related to recreational cocaine use,”
Western Journal of Medicine, vol. 136, no. 5, pp. 444–446, 1982.
[12] R. Virmani, M. Robinowitz, J. E. Smialek, and D. F. Smyth,
“Cardiovascular effects of cocaine: an autopsy study of 40
patients,” American Heart Journal, vol. 115, no. 5, pp. 1068–1076,
1988.
[13] R. A. Lange, R. G. Cigarroa, C. W. Yancy Jr. et al., “Cocaine-
induced coronary-artery vasoconstriction,” The New England
Journal of Medicine, vol. 321, no. 23, pp. 1557–1562, 1989.
[14] B. G. Schwartz, S. Rezkalla, and R. A. Kloner, “Cardiovascular
effects of cocaine,” Circulation, vol. 122, no. 24, pp. 2558–2569,
2010.
[15] S. Maraj, V. M. Figueredo, and D. L. Morris, “Cocaine and the
heart,” Clinical Cardiology, vol. 33, no. 5, pp. 264–269, 2010.
[16] R. A. Lange and L. D. Hillis, “Cardiovascular complications of
cocaine use,”TheNew England Journal of Medicine, vol. 345, no.
5, pp. 351–358, 2001.
[17] J. A. Feldman, S. S. Fish, J. R. Beshansky, J. L. Griffith, R. H.
Woolard, and H. P. Selker, “Acute cardiac ischemia in patients
with cocaine-associated complaints: results of a multicenter
trial,”Annals of EmergencyMedicine, vol. 36, no. 5, pp. 469–476,
2000.
[18] J. E. Weber, C. R. Chudnofsky, M. Boczar, E. W. Boyer, M. D.
Wilkerson, and J. E. Hollander, “Cocaine-associated chest pain:
how common is myocardial infarction?” Academic Emergency
Medicine, vol. 7, no. 8, pp. 873–877, 2000.
[19] P. M. Kanani, P. A. Guse, W. M. Smith, A. Barnett, and
E. H. Ellinwood Jr., “Acute deleterious effects of cocaine on
cardiac conduction, hemodynamics, and ventricular fibrillation
threshold: effects of interaction with a selective dopamine D1
antagonist SCH 39166,” Journal of Cardiovascular Pharmacol-
ogy, vol. 32, no. 1, pp. 42–48, 1998.
[20] A. Frustaci, M. A. Russo, E. Morgante et al., “Oxidative myocar-
dial damage in human cocaine-related cardiomyopathy,” Free
Radical Biology & Medicine, vol. 17, no. 3, pp. 283–290, 2015.
[21] R. J. Henning and Y. Li, “Cocaine produces cardiac hypertrophy
by protein kinase C dependent mechanisms,” Journal of Cardio-
vascular Pharmacology and Therapeutics, vol. 8, no. 2, pp. 149–
160, 2003.
[22] M. E. Brickner, J. E. Willard, E. J. Eichhorn, J. Black, and
P. A. Grayburn, “Left ventricular hypertrophy associated with
chronic cocaine abuse,” Circulation, vol. 84, no. 3, pp. 1130–1135,
1991.
[23] J. L. Pilgrim, N. Woodford, and O. H. Drummer, “Cocaine in
sudden and unexpected death: a review of 49 post-mortem
cases,” Forensic Science International, vol. 227, no. 1–3, pp. 52–
59, 2013.
[24] S. Darke, S. Kaye, and J. Duflou, “Cocaine-related fatalities
in New South Wales, Australia 1993–2002,” Drug and Alcohol
Dependence, vol. 77, no. 2, pp. 107–114, 2005.
[25] EMCDDA, European Monitoring Centre for Drugs
and Drug Addiction, Lisbon, Portugal, 2014,
http://www.emcdda.europa.eu/edr.
[26] J. McCord, H. Jneid, J. E. Hollander et al., “Management
of cocaine-associated chest pain and myocardial infarction:
a scientific statement from theAmerican Heart Association
Acute Cardiac Care Committee of the Council on Clinical
Cardiology,” Circulation, vol. 117, no. 14, pp. 1897–1907, 2008.
[27] N. Gupta, J. B.Washam, S. E.Mountantonakis et al., “Character-
istics, management, and outcomes of cocaine-positive patients
with acute coronary syndrome (from the National Cardiovas-
cular Data Registry),” American Journal of Cardiology, vol. 113,
no. 5, pp. 749–756, 2014.
[28] S. B. Karch, “Cardiac arrest in cocaine users,” The American
Journal of Emergency Medicine, vol. 14, no. 1, pp. 79–81, 1996.
[29] A. Silvanto, S. V. de Noronha, andM. N. Sheppard, “Myocardial
infarction with normal coronaries: an autopsy perspective,”
Journal of Clinical Pathology, vol. 65, no. 6, pp. 512–516, 2012.
[30] L. Liaudet, B. Calderari, and P. Pacher, “Pathophysiologi-
cal mechanisms of catecholamine and cocaine-mediated car-
diotoxicity,” Heart Failure Reviews, vol. 19, no. 6, pp. 815–824,
2014.
[31] R. V. Stankowski, R. A. Kloner, and S. H. Rezkalla, “Cardiovas-
cular consequences of cocaine use,” Trends in Cardiovascular
Medicine, vol. 25, no. 6, pp. 517–526, 2015.
[32] E. Turillazzi, S. Bello, M. Neri, C. Pomara, I. Riezzo, and V.
Fineschi, “Cardiovascular effects of cocaine: cellular, ionic and
molecular mechanisms,” Current Medicinal Chemistry, vol. 19,
no. 33, pp. 5664–5676, 2012.
[33] K. Phillips, A. Luk, G. S. Soor, J. R. Abraham, S. Leong, and
J. Butany, “Cocaine cardiotoxicity: a review of the pathophys-
iology, pathology, and treatment options,” American Journal of
Cardiovascular Drugs, vol. 9, no. 3, pp. 177–196, 2009.
[34] A. Sarkar, A. Pande, G. S. Naveen Chandra, and I. Ahmed,
“Acute myocardial infarction in a young cocaine addict with
normal coronaries: time to raise awareness among emergency
physicians,” Indian Journal of Critical Care Medicine, vol. 17, no.
1, pp. 56–58, 2013.
[35] D. M. Wood, P. I. Dargan, and R. S. Hoffman, “Management
of cocaine-induced cardiac arrhythmias due to cardiac ion
channel dysfunction,” Clinical Toxicology, vol. 47, no. 1, pp. 14–
23, 2009.
[36] D. J. Heal, J. Gosden, and S. L. Smith, “Dopamine reuptake
transporter (DAT) “inverse agonism”— a novel hypothesis to
explain the enigmatic pharmacology of cocaine,”Neuropharma-
cology, vol. 87, pp. 19–40, 2014.
[37] M. W. Fischman, C. R. Schuster, L. Resnekov et al., “Cardiovas-
cular and subjective effects of intravenous cocaine administra-
tion in humans,” Archives of General Psychiatry, vol. 33, no. 8,
pp. 983–989, 1976.
[38] W. Vongpatanasin, Y. Mansour, B. Chavoshan, D. Arbique, and
R. G. Victor, “Cocaine stimulates the human cardiovascular
system via a central mechanism of action,” Circulation, vol. 100,
no. 5, pp. 497–502, 1999.
[39] W. Kerns II, L. Garvey, and J. Owens, “Cocaine-induced wide
complex dysrhythmia,”The Journal of Emergency Medicine, vol.
15, no. 3, pp. 321–329, 1997.
[40] V. M. Costa, F. Carvalho, M. L. Bastos, R. A. Carvalho,
M. Carvalho, and F. Remia˜o, “Contribution of catecholamine
reactive intermediates and oxidative stress to the pathologic
features of heart diseases,” Current Medicinal Chemistry, vol. 18,
no. 15, pp. 2272–2314, 2011.
[41] B. J. Borkowski, Y. Cheema, A. U. Shahbaz, S. K. Bhattacharya,
and K. T. Weber, “Cation dyshomeostasis and cardiomyocyte
10 Oxidative Medicine and Cellular Longevity
necrosis: the Fleckenstein hypothesis revisited,” EuropeanHeart
Journal, vol. 32, no. 15, pp. 1846–1853, 2011.
[42] M. J. Brown, D. C. Brown, and M. B. Murphy, “Hypokalemia
from beta2-receptor stimulation by circulating epinephrine,”
TheNew England Journal of Medicine, vol. 309, no. 23, pp. 1414–
1419, 1983.
[43] K. Ueshima, H. Tachibana, T. Suzuki, and K. Hiramori, “Factors
affecting the blood concentration of ionized magnesium in
patients in the acute phase of myocardial infarction,”Heart and
Vessels, vol. 19, no. 6, pp. 267–270, 2004.
[44] A. A. McDonough, J. B. Velotta, R. H. G. Schwinger, K.
D. Philipson, and R. A. Farley, “The cardiac sodium pump:
structure and function,” Basic Research in Cardiology, vol. 97,
supplement 1, pp. 19–24, 2002.
[45] M. U. Khan, B. O. Komolafe, and K. T. Weber, “Cation
interdependency in acute stressor states,”The American Journal
of the Medical Sciences, vol. 345, no. 5, pp. 401–404, 2013.
[46] A. Fleckenstein, J. Janke, H. J. Do¨ring, and O. Leder, “Myocar-
dial fiber necrosis due to intracellular Ca overload—a new prin-
ciple in cardiac pathophysiology,” Recent Advances in Studies on
Cardiac Structure and Metabolism, vol. 4, pp. 563–580, 1974.
[47] D. M. Bers, “Cardiac excitation-contraction coupling,” Nature,
vol. 415, no. 6868, pp. 198–205, 2002.
[48] R.-P. Xiao, H. Cheng, Y.-Y. Zhou,M. Kuschel, and E. G. Lakatta,
“Recent advances in cardiac𝛽2-adrenergic signal transduction,”
Circulation Research, vol. 85, no. 11, pp. 1092–1100, 1999.
[49] S. Orrenius, V. Gogvadze, and B. Zhivotovsky, “Calcium and
mitochondria in the regulation of cell death,” Biochemical and
Biophysical Research Communications, vol. 460, no. 1, pp. 72–81,
2015.
[50] J. J. Lemasters, T. Qian, C. A. Bradham et al., “Mitochondrial
dysfunction in the pathogenesis of necrotic and apoptotic cell
death,” Journal of Bioenergetics and Biomembranes, vol. 31, no.
4, pp. 305–319, 1999.
[51] A. I. Tarasov, E. J. Griffiths, andG. A. Rutter, “Regulation of ATP
production by mitochondrial Ca2+,” Cell Calcium, vol. 52, no. 1,
pp. 28–35, 2012.
[52] G. S. Behonick, M. J. Novak, E. W. Nealley, and S. I. Baskin,
“Toxicology update: the cardiotoxicity of the oxidative stress
metabolites of catecholamines (aminochromes),” Journal of
Applied Toxicology, vol. 21, supplement 1, pp. S15–S22, 2001.
[53] N. S.Dhalla, A.Adameova, andM.Kaur, “Role of catecholamine
oxidation in sudden cardiac death,” Fundamental & Clinical
Pharmacology, vol. 24, no. 5, pp. 539–546, 2010.
[54] J. L. Rouleau, B. Pitt, N. S. Dhalla et al., “Prognostic importance
of the oxidized product of catecholamines, adrenolutin, in
patients with severe heart failure,” American Heart Journal, vol.
145, no. 5, pp. 926–932, 2003.
[55] D. Cerretani, V. Fineschi, S. Bello, I. Riezzo, E. Turillazzi, andM.
Neri, “Role of oxidative stress in cocaine-induced cardiotoxicity
and cocaine-related death,” Current Medicinal Chemistry, vol.
19, no. 33, pp. 5619–5623, 2012.
[56] V. M. Costa, F. Carvalho, J. A. Duarte, M. D. L. Bastos, and
F. Remia˜o, “The heart as a target for xenobiotic toxicity: the
cardiac susceptibility to oxidative stress,” Chemical Research in
Toxicology, vol. 26, no. 9, pp. 1285–1311, 2013.
[57] L. Xiao, D. R. Pimentel, J. Wang, K. Singh, W. S. Colucci, and
D. B. Sawyer, “Role of reactive oxygen species and NAD(P)H
oxidase in 𝛼
1
-adrenoceptor signaling in adult rat cardiac
myocytes,”American Journal of Physiology—Cell Physiology, vol.
282, no. 4, pp. C926–C934, 2002.
[58] C. E. Murdoch, M. Zhang, A. C. Cave, and A. M. Shah,
“NADPH oxidase-dependent redox signalling in cardiac hyper-
trophy, remodelling and failure,” Cardiovascular Research, vol.
71, no. 2, pp. 208–215, 2006.
[59] F. Moritz, C. Monteil, M. Isabelle et al., “Role of reactive oxygen
species in cocaine-induced cardiac dysfunction,” Cardiovascu-
lar Research, vol. 59, no. 4, pp. 834–843, 2003.
[60] T. Ago, J. Kuroda, M. Kamouchi, J. Sadoshima, and T. Kitazono,
“Pathophysiological roles of NADPH oxidase/Nox family pro-
teins in the vascular system—review and perspective,” Circula-
tion Journal, vol. 75, no. 8, pp. 1791–1800, 2011.
[61] K. Bedard and K.-H. Krause, “The NOX family of ROS-
generatingNADPHoxidases: physiology and pathophysiology,”
Physiological Reviews, vol. 87, no. 1, pp. 245–313, 2007.
[62] H. Sumimoto, “Structure, regulation and evolution of Nox-
family NADPH oxidases that produce reactive oxygen species,”
FEBS Journal, vol. 275, no. 13, pp. 3249–3277, 2008.
[63] F. Xiong, D. Xiao, and L. Zhang, “Norepinephrine causes
epigenetic repression of PKC𝜀 gene in rodent hearts by activat-
ing Nox1-dependent reactive oxygen species production,” The
FASEB Journal, vol. 26, no. 7, pp. 2753–2763, 2012.
[64] M. Isabelle, A. Vergeade, F. Moritz et al., “NADPH oxidase
inhibition prevents cocaine-induced up-regulation of xanthine
oxidoreductase and cardiac dysfunction,” Journal of Molecular
and Cellular Cardiology, vol. 42, no. 2, pp. 326–332, 2007.
[65] A. Vergeade, P. Mulder, C. Vendeville, R. Ventura-Clapier, C.
Thuillez, and C. Monteil, “Xanthine oxidase contributes to
mitochondrial ROS generation in an experimental model of
cocaine-induced diastolic dysfunction,” Journal of Cardiovascu-
lar Pharmacology, vol. 60, no. 6, pp. 538–543, 2012.
[66] D.C.Andersson, J. Fauconnier, T. Yamada et al., “Mitochondrial
production of reactive oxygen species contributes to the 𝛽-
adrenergic stimulation of mouse cardiomycytes,”The Journal of
Physiology, vol. 589, no. 7, pp. 1791–1801, 2011.
[67] A. Vergeade, P. Mulder, C. Vendeville-Dehaudt et al., “Mito-
chondrial impairment contributes to cocaine-induced cardiac
dysfunction: prevention by the targeted antioxidant MitoQ,”
Free Radical Biology and Medicine, vol. 49, no. 5, pp. 748–756,
2010.
[68] A. F. Branco, S. F. Sampaio,M. R.Wieckowski, V. A. Sarda˜o, and
P. J. Oliveira, “Mitochondrial disruption occurs downstream
from 𝛽-adrenergic overactivation by isoproterenol in differen-
tiated, but not undifferentiated H9c2 cardiomyoblasts: differ-
ential activation of stress and survival pathways,” International
Journal of Biochemistry andCell Biology, vol. 45, no. 11, pp. 2379–
2391, 2013.
[69] S. Papa, “The NDUFS4 nuclear gene of complex I of mitochon-
dria and the cAMP cascade,” Biochimica et Biophysica Acta—
Bioenergetics, vol. 1555, no. 1–3, pp. 147–153, 2002.
[70] S. Nagasaka, H. Katoh, F. N. Chun et al., “Protein kinase
A catalytic subunit alters cardiac mitochondrial redox state
and membrane potential via the formation of reactive oxygen
species,” Circulation Journal, vol. 71, no. 3, pp. 429–436, 2007.
[71] S. Srivastava, B. Chandrasekar, Y. Gu et al., “Downregulation
of CuZn-superoxide dismutase contributes to 𝛽-adrenergic
receptor-mediated oxidative stress in the heart,” Cardiovascular
Research, vol. 74, no. 3, pp. 445–455, 2007.
[72] L. Lai, L. Yan, S. Gao et al., “Type 5 adenylyl cyclase increases
oxidative stress by transcriptional regulation of manganese
superoxide dismutase via the SIRT1/FoxO3a pathway,” Circula-
tion, vol. 127, no. 16, pp. 1692–1701, 2013.
Oxidative Medicine and Cellular Longevity 11
[73] A. Adameova, Y. Abdellatif, andN. S. Dhalla, “Role of the exces-
sive amounts of circulating catecholamines and glucocorticoids
in stress-induced heart disease,” Canadian Journal of Physiology
and Pharmacology, vol. 87, no. 7, pp. 493–514, 2009.
[74] V. M. Costa, R. Silva, L. M. Ferreira et al., “Oxidation process
of adrenaline in freshly isolated rat cardiomyocytes: formation
of adrenochrome, quinoproteins, and GSH adduct,” Chemical
Research in Toxicology, vol. 20, no. 8, pp. 1183–1191, 2007.
[75] M. Neri, D. Cerretani, A. I. Fiaschi et al., “Correlation between
cardiac oxidative stress and myocardial pathology due to acute
and chronic norepinephrine administration in rats,” Journal of
Cellular andMolecular Medicine, vol. 11, no. 1, pp. 156–170, 2007.
[76] A. F. E. Rump, J. Schierholz, and W. Klaus, “Studies on
the cardiotoxicity of noradrenaline in isolated rabbit hearts,”
Arzneimittel-Forschung, vol. 52, no. 7, pp. 543–551, 2002.
[77] P. Hasˇkova´, P. Kovarˇ´ıkova´, L. Koubkova´, A. Va´vrova´, E.
MacKova´, and T. Sˇimu˚nek, “Iron chelation with salicylaldehyde
isonicotinoyl hydrazone protects against catecholamine autoxi-
dation and cardiotoxicity,” Free Radical Biology &Medicine, vol.
50, no. 4, pp. 537–549, 2011.
[78] M. S. Wolin and F. L. Belloni, “Superoxide anion selectively
attenuates catecholamine-induced contractile tension in iso-
lated rabbit aorta,”TheAmerican Journal of Physiology, vol. 249,
no. 6, pp. H1127–H1133, 1985.
[79] F. Remia˜o, M. Carvalho, H. Carmo, F. Carvalho, and M.
L. Bastos, “Cu2+-induced isoproterenol oxidation into iso-
prenochrome in adult rat calcium-tolerant cardiomyocytes,”
Chemical Research inToxicology, vol. 15, no. 6, pp. 861–869, 2002.
[80] P. Hasˇkova´, L. Koubkova´, A. Va´vrova´ et al., “Comparison of
various iron chelators used in clinical practice as protecting
agents against catecholamine-induced oxidative injury and
cardiotoxicity,” Toxicology, vol. 289, no. 2-3, pp. 122–131, 2011.
[81] K. P. Minneman, “𝛼1-Adrenergic receptor subtypes, inositol
phosphates, and sources of cell Ca2+,” Pharmacological Reviews,
vol. 40, no. 2, pp. 87–119, 1988.
[82] J. R. Docherty, “Subtypes of functional 𝛼1-adrenoceptor,” Cellu-
lar and Molecular Life Sciences, vol. 67, no. 3, pp. 405–417, 2010.
[83] D. M. Perez, “Structure-function of 𝛼
1
-adrenergic receptors,”
Biochemical Pharmacology, vol. 73, no. 8, pp. 1051–1062, 2007.
[84] L. Pradhan, D. Mondal, S. Chandra, M. Ali, and K. C. Agrawal,
“Molecular analysis of cocaine-induced endothelial dysfunc-
tion: role of endothelin-1 and nitric oxide,” Cardiovascular
Toxicology, vol. 8, no. 4, pp. 161–171, 2008.
[85] E. P. Havranek, K. Nademanee, P. A. Grayburn, and E. J.
Eichhorn, “Endothelium-dependent vasorelaxation is impaired
in cocaine arteriopathy,” Journal of the American College of
Cardiology, vol. 28, no. 5, pp. 1168–1174, 1996.
[86] G. I. Togna, M. Graziani, P. Russo, and L. Caprino, “Cocaine
toxic effect on endothelium-dependent vasorelaxation: an in
vitro study on rabbit aorta,” Toxicology Letters, vol. 123, no. 1,
pp. 43–50, 2001.
[87] J. He, S. Yang, and L. Zhang, “Effects of cocaine on nitric oxide
production in bovine coronary artery endothelial cells,” Journal
of Pharmacology and Experimental Therapeutics, vol. 314, no. 3,
pp. 980–986, 2005.
[88] C. G. Sa´ez, P. Olivares, J. Pallavicini et al., “Increased number of
circulating endothelial cells and plasma markers of endothelial
damage in chronic cocaine users,”Thrombosis Research, vol. 128,
no. 4, pp. e18–e23, 2011.
[89] M. I. Mendoza-Baumgart, M. Pravetoni, and S. B. Sparber,
“Inhibition of nitric oxide synthase enhances cocaine’s devel-
opmental toxicity: vascular and CNS effects,”Neuropsychophar-
macology, vol. 32, no. 4, pp. 940–945, 2007.
[90] D. Ramzy, V. Rao, L. C. Tumiati et al., “Elevated endothelin-
1 levels impair nitric oxide homeostasis through a PKC-
dependent pathway,” Circulation, vol. 114, no. 1, pp. I319–I326,
2006.
[91] R. Lo´pez-Sepu´lveda, M. Go´mez-Guzma´n, M. J. Zarzuelo et
al., “Red wine polyphenols prevent endothelial dysfunction
induced by endothelin-1 in rat aorta: role of NADPH oxidase,”
Clinical Science, vol. 120, no. 8, pp. 321–333, 2011.
[92] S. Wedgwood and S. M. Black, “Endothelin-1 decreases
endothelial NOS expression and activity through ETA receptor-
mediated generation of hydrogen peroxide,” American Journal
of Physiology—Lung Cellular andMolecular Physiology, vol. 288,
no. 3, pp. L480–L487, 2005.
[93] U. Landmesser, B. Hornig, and H. Drexler, “Endothelial func-
tion: a critical determinant in atherosclerosis?” Circulation, vol.
109, supplement 1, no. 21, pp. 27–33, 2004.
[94] R. Patrizi, V. Pasceri, A. Sciahbasi, F. Summaria, G. M. C.
Rosano, and E. Lioy, “Evidence of cocaine-related coronary
atherosclerosis in young patients with myocardial infarction,”
Journal of the American College of Cardiology, vol. 47, no. 10, pp.
2120–2122, 2006.
[95] M. R. Dashwood and J. C. S. Tsui, “Further evidence for a role
of endothelin-1 (ET-1) in critical limb ischaemia,” Journal of Cell
Communication and Signaling, vol. 5, no. 1, pp. 45–49, 2011.
[96] E. D. Flores, R. A. Lange, R. G. Cigarroa, and L. D. Hillis, “Effect
of cocaine on coronary artery dimensions in atherosclerotic
coronary artery disease: enhanced vasoconstriction at sites
of significant stenoses,” Journal of the American College of
Cardiology, vol. 16, no. 1, pp. 74–79, 1990.
[97] J. L. Cook and C. L. Randall, “Cocaine does not affect prosta-
cyclin, thromboxane or prostaglandin E production in human
umbilical veins,” Drug and Alcohol Dependence, vol. 41, no. 2,
pp. 113–118, 1996.
[98] D. S. Mastrogiannis and W. F. O’Brien, “Cocaine affects
prostaglandin production in human umbilical cord cell cul-
tures,” The Journal of Maternal-Fetal & Neonatal Medicine, vol.
14, no. 4, pp. 261–266, 2003.
[99] G. Togna, M. Graziani, C. Sorrentino, and L. Caprino,
“Prostanoid production in the presence of platelet activation in
hypoxic cocaine-treated rats,” Haemostasis, vol. 26, no. 6, pp.
311–318, 1996.
[100] M. M. Hynynen and R. A. Khalil, “The vascular endothelin sys-
tem in hypertension—recent patents and discoveries.,” Recent
Patents on Cardiovascular Drug Discovery, vol. 1, no. 1, pp. 95–
108, 2006.
[101] W. E. Hobbs, E. E. Moore, R. A. Penkala, D. D. Bolgiano,
and J. A. Lo´pez, “Cocaine and specific cocaine metabolites
induce von Willebrand factor release from endothelial cells
in a tissue-specific manner,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 33, no. 6, pp. 1230–1237, 2013.
[102] G. Togna, E. Tempesta, A. R. Togna, N. Dolci, B. Cebo,
and L. Caprino, “Platelet responsiveness and biosynthesis of
thromboxane and prostacyclin in response to in vitro cocaine
treatment,” Haemostasis, vol. 15, no. 2, pp. 100–107, 1985.
[103] A. D. Kugelmass, R. P. Shannon, E. L. Yeo, and J. A. Ware,
“Intravenous cocaine induces platelet activation in the con-
scious dog,” Circulation, vol. 91, no. 5, pp. 1336–1340, 1995.
12 Oxidative Medicine and Cellular Longevity
[104] L. K. Jennings, M. M. White, C. M. Sauer, A. M. Mauer, and J.
T. Robertson, “Cocaine-induced platelet defects,” Stroke, vol. 24,
no. 9, pp. 1352–1359, 1993.
[105] S. H. Rezkalla, J. J. Mazza, R. A. Kloner, V. Tillema, and S.-
H. Chang, “Effects of cocaine on human platelets in healthy
subjects,”The American Journal of Cardiology, vol. 72, no. 2, pp.
243–246, 1993.
[106] A. D. Kugelmass, A. Oda, K. Monahan, C. Cabral, and J. A.
Ware, “Activation of human platelets by cocaine,” Circulation,
vol. 88, no. 3, pp. 876–883, 1993.
[107] H. M. Rinder, K. A. Ault, P. I. Jatlow, T. R. Kosten, and B. R.
Smith, “Platelet 𝛼-granule release in cocaine users,” Circulation,
vol. 90, no. 3, pp. 1162–1167, 1994.
[108] C. M. Heesch, C. R. Wilhelm, J. Ristich, J. Adnane, F. A.
Bontempo, and W. R. Wagner, “Cocaine activates platelets
and increases the formation of circulating platelet containing
microaggregates in humans,” Heart, vol. 83, no. 6, pp. 688–695,
2000.
[109] J. Pereira, C. G. Sa´ez, J. Pallavicini et al., “Platelet activation in
chronic cocaine users: effect of short term abstinence,” Platelets,
vol. 22, no. 8, pp. 596–601, 2011.
[110] M. Kiebala, M. V. Singh, M. S. Piepenbrink, X. Qiu, J. J.
Kobie, and S. B. Maggirwar, “Platelet activation in human
immunodeficiency virus type-1 patients is not altered with
cocaine abuse,” PLoS ONE, vol. 10, no. 6, Article ID e0130061,
2015.
[111] C. Aoui, A. Prigent, C. Sut et al., “The signaling role of
cd40 ligand in platelet biology and in platelet component
transfusion,” International Journal of Molecular Sciences, vol. 15,
no. 12, pp. 22342–22364, 2014.
[112] J. S. McNally, M. E. Davis, D. P. Giddens et al., “Role of
xanthine oxidoreductase and NAD(P)H oxidase in endothelial
superoxide production in response to oscillatory shear stress,”
The American Journal of Physiology—Heart and Circulatory
Physiology, vol. 285, no. 6, pp. H2290–H2297, 2003.
[113] U. Landmesser, S. Dikalov, S. R. Price et al., “Oxidation of
tetrahydrobiopterin leads to uncoupling of endothelial cell
nitric oxide synthase in hypertension,” The Journal of Clinical
Investigation, vol. 111, no. 8, pp. 1201–1209, 2003.
[114] J. F. Turrens, “Mitochondrial formation of reactive oxygen
species,” Journal of Physiology, vol. 552, no. 2, pp. 335–344, 2003.
[115] Z. Q. Zhao, “Mitochondrial formation of reactive oxygen
species. Oxidative stress-elicited myocardial apoptosis during
reperfusion,”Current Opinion in Pharmacology, vol. 4, no. 2, pp.
159–165, 2004.
[116] V. Darley-Usmar, “The powerhouse takes control of the cell;
the role of mitochondria in signal transduction,” Free Radical
Biology and Medicine, vol. 37, no. 6, pp. 753–754, 2004.
[117] N. Kaludercic, J. Mialet-Perez, N. Paolocci, A. Parini, and F. Di
Lisa, “Monoamine oxidases as sources of oxidants in the heart,”
Journal of Molecular and Cellular Cardiology, vol. 73, pp. 34–42,
2014.
[118] F. Carvalho, J. Duarte, M. Neuparth et al., “Hydrogen peroxide
production inmouse tissues after acute d-amphetamine admin-
istration. Influence of monoamine oxidase inhibition,” Archives
of Toxicology, vol. 75, no. 8, pp. 465–469, 2001.
[119] P. Dalvi, K. Wang, J. Mermis et al., “HIV-1/Cocaine induced
oxidative stress disrupts tight junction protein-1 in human pul-
monary microvascular endothelial cells: Role of RAS/ERK1/2
pathway,” PLoS ONE, vol. 9, no. 1, Article ID 0085246, 2014.
[120] H. Cai, “Hydrogen peroxide regulation of endothelial func-
tion: origins, mechanisms, and consequences,” Cardiovascular
Research, vol. 68, no. 1, pp. 26–36, 2005.
[121] D. B. Zorov, M. Juhaszova, and S. J. Sollott, “Mitochondrial
reactive oxygen species (ROS) and ROS-induced ROS release,”
Physiological Reviews, vol. 94, no. 3, pp. 909–950, 2014.
[122] M. A. Aon, S. Cortassa, F. G. Akar, and B. O’Rourke, “Mito-
chondrial criticality: a new concept at the turning point of life or
death,” Biochimica et Biophysica Acta, vol. 1762, no. 2, pp. 232–
240, 2006.
[123] D. B. Zorov, C. R. Filburn, L.-O. Klotz, J. L. Zweier, and
S. J. Sollott, “Reactive oxygen species (ROS)-induced ROS
release: a new phenomenon accompanying induction of the
mitochondrial permeability transition in cardiacmyocytes,”The
Journal of Experimental Medicine, vol. 192, no. 7, pp. 1001–1014,
2000.
[124] B. Lasse`gue, A. San Mart´ın, and K. K. Griendling, “Biochem-
istry, physiology, and pathophysiology of NADPH oxidases in
the cardiovascular system,”Circulation Research, vol. 110, no. 10,
pp. 1364–1390, 2012.
[125] M. A. Kluge, J. L. Fetterman, and J. A. Vita, “Mitochondria and
endothelial function,” Circulation Research, vol. 112, no. 8, pp.
1171–1188, 2013.
[126] L. S. Yoshida and S. Tsunawaki, “Expression of NADPH
oxidases and enhanced H
2
O
2
-generating activity in human
coronary artery endothelial cells upon induction with tumor
necrosis factor-𝛼,” International Immunopharmacology, vol. 8,
no. 10, pp. 1377–1385, 2008.
[127] Y. W. Lee, B. Hennig, M. Fiala, K. S. Kim, and M. Toborek,
“Cocaine activates redox-regulated transcription factors and
induces TNF-𝛼 expression in human brain endothelial cells,”
Brain Research, vol. 920, no. 1-2, pp. 125–133, 2001.
[128] F. Balaguer, J. Ferna´ndez, M. Lozano, R. Miquel, and A. Mas,
“Cocaine-induced acute hepatitis and thrombotic microan-
giopathy,”The Journal of the American Medical Association, vol.
293, no. 7, pp. 797–798, 2005.
[129] M. J. Pe´rez, D.M. Garc´ıa, I. S. Leiva, and R. O. Garc´ıa, “Cocaine-
induced hepatotoxicity,”Medicina Clinica, vol. 130, no. 7, article
279, 2008.
[130] L. E. Perino, G. H. Warren, and J. S. Levine, “Cocaine-induced
hepatotoxicity in humans,” Gastroenterology, vol. 93, no. 1, pp.
176–180, 1987.
[131] I. R. Wanless, S. Dore, N. Gopinath et al., “Histopathology of
cocaine hepatotoxicity. Report of four patients,” Gastroenterol-
ogy, vol. 98, no. 2, pp. 497–501, 1990.
[132] G. C. Kanel, W. Cassidy, L. Shuster, and T. B. Reynolds,
“Cocaine-induced liver cell injury: comparison of morpholog-
ical features in man and in experimental models,” Hepatology,
vol. 11, no. 4, pp. 646–651, 1990.
[133] A. Payance´, B. Scotto, J.-M. Perarnau, A. de Muret, and Y.
Bacq, “Severe chronic hepatitis secondary to prolonged use of
ecstasy and cocaine,” Clinics and Research in Hepatology and
Gastroenterology, vol. 37, no. 5, pp. 109–113, 2013.
[134] R. Kothur, F. Marsh Jr., and G. Posner, “Liver function tests in
nonparenteral cocaine users,”Archives of Internal Medicine, vol.
151, no. 6, pp. 1126–1128, 1991.
[135] V. Vitcheva, “Cocaine toxicity and hepatic oxidative stress,”
Current Medicinal Chemistry, vol. 19, no. 33, pp. 5677–5682,
2012.
[136] I. Riezzo, C. Fiore, D. De Carlo et al., “Side effects of cocaine
abuse: multiorgan toxicity and pathological consequences,”
Oxidative Medicine and Cellular Longevity 13
Current Medicinal Chemistry, vol. 19, no. 33, pp. 5624–5646,
2012.
[137] H. K.Watanabe, B. Hoskins, and I. K. Ho, “Sensitivity difference
to hepatotoxicity of cocaine in spontaneously hypertensive and
Wistar Kyoto rats,” Alcohol and Drug Research, vol. 7, no. 5-6,
pp. 363–370, 1987.
[138] M. L. Thompson, L. Shuster, and K. Shaw, “Cocaine-induced
hepatic necrosis in mice—the role of cocaine metabolism,”
Biochemical Pharmacology, vol. 28, no. 15, pp. 2389–2395, 1979.
[139] F. M. Ndikum-Moffor, T. R. Schoeb, and S. M. Roberts, “Liver
toxicity from norcocaine nitroxide, an N-oxidative metabolite
of cocaine,” Journal of Pharmacology and Experimental Thera-
peutics, vol. 284, no. 1, pp. 413–419, 1998.
[140] P. Kovacic, “Role of oxidative metabolites of cocaine in toxicity
and addiction: oxidative stress and electron transfer,” Medical
Hypotheses, vol. 64, no. 2, pp. 350–356, 2005.
[141] L. M. Bornheim, “Effect of cytochrome P450 inducers on
cocaine-mediated hepatotoxicity,” Toxicology and Applied Phar-
macology, vol. 150, no. 1, pp. 158–165, 1998.
[142] K. Aoki, M. Takimoto, H. Ota, and T. Yoshida, “Participation
of CYP2A in cocaine-induced hepatotoxicity in female mice,”
Pharmacology & Toxicology, vol. 87, no. 1, pp. 26–32, 2000.
[143] S. Z. Mehanny and M. S. Abdel-Rahman, “Cocaine hepato-
toxicity in mice: histologic and enzymatic studies,” Toxicologic
Pathology, vol. 19, no. 1, pp. 24–29, 1991.
[144] M. A. Evans and R. D. Harbison, “Cocaine-induced hepatotoxi-
city in mice,” Toxicology and Applied Pharmacology, vol. 45, no.
3, pp. 739–754, 1978.
[145] R. Labib, M. S. Abdel-Rahman, and R. Turkall, “N-
acetylcysteine pretreatment decreases cocaine and
endotoxin-induced hepatotoxicity,” Journal of Toxicology
and Environmental Health, vol. 66, no. 3, pp. 223–239, 2003.
[146] R. Labib, R. Turkall, and M. S. Abdel-Rahman, “Endotoxin
potentiates cocaine-mediated hepatotoxicity by nitric oxide and
reactive oxygen species,” International Journal of Toxicology, vol.
22, no. 4, pp. 305–316, 2003.
[147] U. A. Boelsterli and C. Goldlin, “Biomechanisms of cocaine-
induced hepatocyte injury mediated by the formation of reac-
tive metabolites,” Archives of Toxicology, vol. 65, no. 5, pp. 351–
360, 1991.
[148] A. Masini, D. Gallesi, F. Giovannini, T. Trenti, and D. Cec-
carelli, “Membrane potential of hepatic mitochondria after
acute cocaine administration in rats—the role of mitochondrial
reduced glutathione,” Hepatology, vol. 25, no. 2, pp. 385–390,
1997.
[149] B. G. Devi and A. W. K. Chan, “Impairment of mitochon-
drial respiration and electron transport chain enzymes during
cocaine-induced hepatic injury,” Life Sciences, vol. 60, no. 11, pp.
849–855, 1997.
[150] F. Boess, F. M. Ndikum-Moffor, U. A. Boelsterli, and S. M.
Roberts, “Effects of cocaine and its oxidative metabolites on
mitochondrial respiration and generation of reactive oxygen
species,” Biochemical Pharmacology, vol. 60, no. 5, pp. 615–623,
2000.
[151] D. A. Donnelly, C. S. Boyer, D. R. Petersen, and D. Ross,
“Cocaine-induced biochemical changes and cytotoxicity in
hepatocytes isolated from both mice and rats,” Chemico-
Biological Interactions, vol. 67, no. 1-2, pp. 95–104, 1988.
[152] C. R. Go¨ldlin and U. A. Boelsterli, “Reactive oxygen species and
non-peroxidative mechanisms of cocaine-induced cytotoxicity
in rat hepatocyte cultures,” Toxicology, vol. 69, no. 1, pp. 79–91,
1991.
[153] S. Connors, D. R. Rankin, A. J. Gandolfi, C. L. Krumdieck, L. J.
Koep, and K. Brendel, “Cocaine hepatotoxicity in cultured liver
slices: a species comparison,” Toxicology, vol. 61, no. 2, pp. 171–
183, 1990.
[154] C. Go¨ldlin and U. A. Boelsterli, “Dissociation of covalent
protein adduct formation from oxidative injury in cultured
hepatocytes exposed to cocaine,” Xenobiotica, vol. 24, no. 3, pp.
251–264, 1994.
[155] C. Dı´ez-Ferna´ndez, A. Zaragoza, A. M. Alvarez, and M.
Cascales, “Cocaine cytotoxicity in hepatocyte cultures from
phenobarbital-induced rats: involvement of reactive oxygen
species and expression of antioxidant defense systems,” Bio-
chemical Pharmacology, vol. 58, no. 5, pp. 797–805, 1999.
[156] A. Zaragoza, C. Dı´ez-Ferna´ndez, A. M. Alvarez, D. Andre´s,
and M. Cascales, “Effect of N-acetylcysteine and deferoxamine
on endogenous antioxidant defense system gene expression in
a rat hepatocyte model of cocaine cytotoxicity,” Biochimica et
Biophysica Acta, vol. 1496, no. 2-3, pp. 183–195, 2000.
[157] O. Dean, F. Giorlando, and M. Berk, “N-acetylcysteine in
psychiatry: current therapeutic evidence and potential mech-
anisms of action,” Journal of Psychiatry and Neuroscience, vol.
36, no. 2, pp. 78–86, 2011.
[158] D. Deepmala, J. Slattery, N. Kumar et al., “Clinical trials of
N-acetylcysteine in psychiatry and neurology: a systematic
review,”Neuroscience & Biobehavioral Reviews, vol. 55, pp. 294–
321, 2015.
[159] E. A.McClure, C. D. Gipson, R. J.Malcolm, P.W. Kalivas, andK.
M. Gray, “Potential role of N-acetylcysteine in the management
of substance use disorders,” CNS Drugs, vol. 28, no. 2, pp. 95–
106, 2014.
[160] M. Berk, G. S. Malhi, L. J. Gray, and O. M. Dean, “The
promise of N-acetylcysteine in neuropsychiatry,” Trends in
Pharmacological Sciences, vol. 34, no. 3, pp. 167–177, 2013.
[161] S. D. LaRowe, P. W. Kalivas, J. S. Nicholas, P. K. Randall, P.
N. Mardikian, and R. J. Malcolm, “A double-blind placebo-
controlled trial of N-acetylcysteine in the treatment of cocaine
dependence,” The American Journal on Addictions, vol. 22, no.
5, pp. 443–452, 2013.
[162] D. A. Baker, K. McFarland, R.W. Lake et al., “Neuroadaptations
in cystine-glutamate exchange underlie cocaine relapse,”Nature
Neuroscience, vol. 6, no. 7, pp. 743–749, 2003.
[163] E. Asevedo, A. C.Mendes,M. Berk, and E. Brietzke, “Systematic
review of N-acetylcysteine in the treatment of addictions,”
Revista Brasileira de Psiquiatria, vol. 36, no. 2, pp. 168–175, 2014.
[164] A. Gillissen, B. Scha¨rling, M. Jaworska, A. Bartling, K. Rasche,
and G. Schultze-Werninghaus, “Oxidant scavenger function
of ambroxol in vitro: a comparison with N-acetylcysteine,”
Research in Experimental Medicine, vol. 196, no. 6, pp. 389–398,
1997.
[165] L. Zhang, Z. Zhu, J. Liu, Z. Zhu, and Z. Hu, “Protective effect of
N-acetylcysteine (NAC) on renal ischemia/reperfusion injury
throughNrf2 signaling pathway,” Journal of Receptors and Signal
Transduction, vol. 34, no. 5, pp. 396–400, 2014.
[166] J. L. Lim, M. M. M. Wilhelmus, H. E. de Vries, B. Drukarch, J.
J. M. Hoozemans, and J. van Horssen, “Antioxidative defense
mechanisms controlled by Nrf2: state-of-the-art and clinical
perspectives in neurodegenerative diseases,”Archives of Toxicol-
ogy, vol. 88, no. 10, pp. 1773–1786, 2014.
[167] G. R. Buettner, “Superoxide dismutase in redox biology: the
roles of superoxide and hydrogen peroxide,”Anti-Cancer Agents
in Medicinal Chemistry, vol. 11, no. 4, pp. 341–346, 2011.
14 Oxidative Medicine and Cellular Longevity
[168] D. Salvemini, D. P. Riley, and S. Cuzzocrea, “SOD mimetics are
coming of age,”Nature Reviews Drug Discovery, vol. 1, no. 5, pp.
367–374, 2002.
[169] J. B. de Haan andM. E. Cooper, “Targeted antioxidant therapies
in hyperglycemia-mediated endothelial dysfunction,” Frontiers
in Bioscience: Scholar, vol. 3, no. 2, pp. 709–729, 2011.
[170] R. A. Floyd, R. D. Kopke, C.-H. Choi, S. B. Foster, S. Doblas, and
R. A. Towner, “Nitrones as therapeutics,” Free Radical Biology &
Medicine, vol. 45, no. 10, pp. 1361–1374, 2008.
[171] E. D. Hall, “Antioxidant therapies for acute spinal cord injury,”
Neurotherapeutics, vol. 8, no. 2, pp. 152–167, 2011.
[172] R. Numa, R. Kohen, T. Poltyrev, and R. Yaka, “Tempol
diminishes cocaine-induced oxidative damage and attenuates
the development and expression of behavioral sensitization,”
Neuroscience, vol. 155, no. 3, pp. 649–658, 2008.
[173] E. J. Jang, Y. H. Ryu, B. H. Lee et al., “Involvement of reactive
oxygen species in cocaine-taking behaviors in rats,” Addiction
Biology, vol. 15, no. 4, pp. 663–675, 2015.
[174] J. Tinkel, H. Hassanain, and S. J. Khouri, “Cardiovascular
antioxidant therapy: a review of supplements, pharmacothera-
pies, and mechanisms,” Cardiology in Review, vol. 20, no. 2, pp.
77–83, 2012.
[175] L. Rochette, S. Ghibu, C. Richard, M. Zeller, Y. Cottin, and C.
Vergely, “Direct and indirect antioxidant properties of 𝛼-lipoic
acid and therapeutic potential,” Molecular Nutrition and Food
Research, vol. 57, no. 1, pp. 114–125, 2013.
[176] S. Sorce, K.-H. Krause, and V. Jaquet, “Targeting NOX enzymes
in the central nervous system: therapeutic opportunities,” Cel-
lular and Molecular Life Sciences, vol. 69, no. 14, pp. 2387–2407,
2012.
[177] T. Kahles and R. P. Brandes, “NADPH oxidases as therapeutic
targets in ischemic stroke,” Cellular and Molecular Life Sciences,
vol. 69, no. 14, pp. 2345–2363, 2012.
[178] A. Schramm, P. Matusik, G. Osmenda, and T. J. Guzik, “Tar-
geting NADPH oxidases in vascular pharmacology,” Vascular
Pharmacology, vol. 56, no. 5-6, pp. 216–231, 2012.
[179] L. Fan,D. Sawbridge,V.George et al., “Chronic cocaine-induced
cardiac oxidative stress and mitogen-activated protein kinase
activation: the role of Nox2 oxidase,” Journal of Pharmacology
and ExperimentalTherapeutics, vol. 328, no. 1, pp. 99–106, 2009.
[180] P. Pacher, A. Nivorozhkin, and C. Szabo´, “Therapeutic effects of
xanthine oxidase inhibitors: renaissance half a century after the
discovery of allopurinol,” Pharmacological Reviews, vol. 58, no.
1, pp. 87–114, 2006.
[181] D. M. Small, J. S. Coombes, N. Bennett, D. W. Johnson, and G.
C. Gobe, “Oxidative stress, anti-oxidant therapies and chronic
kidney disease,” Nephrology, vol. 17, no. 4, pp. 311–321, 2012.
[182] W. Doehner and U. Landmesser, “Xanthine oxidase and uric
acid in cardiovascular disease: clinical impact and therapeutic
options,” Seminars in Nephrology, vol. 31, no. 5, pp. 433–440,
2011.
[183] K. Aoki, M. Ohmori, M. Takimoto, H. Ota, and T. Yoshida,
“Cocaine-induced liver injury in mice is mediated by nitric
oxide and reactive oxygen species,” European Journal of Phar-
macology, vol. 336, no. 1, pp. 43–49, 1997.
[184] R. A. J. Smith, R. C. Hartley, H. M. Cocheme´, and M. P. Mur-
phy, “Mitochondrial pharmacology,” Trends in Pharmacological
Sciences, vol. 33, no. 6, pp. 341–352, 2012.
[185] R. A. J. Smith and M. P. Murphy, “Mitochondria-targeted
antioxidants as therapies.,”Discoverymedicine, vol. 11, no. 57, pp.
106–114, 2011.
[186] H. H. Szeto, “Cell-permeable, mitochondrial-targeted, peptide
antioxidants,” The AAPS Journal, vol. 8, no. 2, pp. E277–E283,
2006.
[187] A. Sadakierska-Chudy, M. Frankowska, andM. Filip, “Mitoepi-
genetics and drug addiction,”Pharmacology&Therapeutics, vol.
144, no. 2, pp. 226–233, 2014.
[188] A. Zaragoza, C. Dı´ez-Ferna´ndez, A. M. Alvarez, D. Andre´s, and
M. Cascales, “Mitochondrial involvement in cocaine-treated
rat hepatocytes: Effect of N-acetylcysteine and deferoxamine,”
British Journal of Pharmacology, vol. 132, no. 5, pp. 1063–1070,
2001.
[189] F. Moritz, C. Monteil, M. Isabelle et al., “Selenium diet-
supplementation improves cocaine-induced myocardial oxida-
tive stress and prevents cardiac dysfunction in rats,” Fundamen-
tal and Clinical Pharmacology, vol. 18, no. 4, pp. 431–436, 2004.
[190] I. Sinha-Hikim, R. Shen, I. Nzenwa, R. Gelfand, S. K. Mahata,
and A. P. Sinha-Hikim, “Minocycline suppresses oxidative
stress and attenuates fetal cardiac myocyte apoptosis triggered
by in utero cocaine exposure,” Apoptosis, vol. 16, no. 6, pp. 563–
573, 2011.
[191] J. M. Madeira, D. L. Gibson, W. F. Kean, and A. Klegeris, “The
biological activity of auranofin: Implications for novel treatment
of diseases,” Inflammopharmacology, vol. 20, no. 6, pp. 297–306,
2012.
[192] T. Ashino, J. Sugiuchi, J. Uehara et al., “Auranofin protects
against cocaine-induced hepatic injury through induction of
heme oxygenase-1,” Journal of Toxicological Sciences, vol. 36, no.
5, pp. 635–643, 2011.
[193] W. F. Kean, L. Hart, and W. W. Buchanan, “Auranofin,” British
Journal of Rheumatology, vol. 36, no. 5, pp. 560–572, 1997.
[194] I. Tomomi, H. Tsutsui, S. Kinugawa, H. Utsumi, and A.
Takeshita, “Amiodarone protects cardiac myocytes against
oxidative injury by its free radical scavenging action,” Circula-
tion, vol. 100, no. 7, pp. 690–692, 1999.
[195] C. R.DeWitt, N. Cleveland, R. C.Dart, andK.Heard, “The effect
of amiodarone pretreatment on survival of mice with cocaine
toxicity,” Journal of Medical Toxicology, vol. 1, no. 1, pp. 11–18,
2005.
[196] E. A. Kalimullah and S. M. Bryant, “Case files of the medical
toxicology fellowship at the toxikon consortium in Chicago:
cocaine-associated wide-complex dysrhythmias and cardiac
arrest—treatment nuances and controversies,” Journal of Medi-
cal Toxicology, vol. 4, no. 4, pp. 277–283, 2008.
[197] D. A. G. Mickle and R. D. Weisel, “Future directions of vitamin
E and its analogues in minimizing myocarcdial ischemia-
reperfusion injury,” Canadian Journal of Cardiology, vol. 9, no.
1, pp. 89–93, 1993.
[198] M. Y. Aksenov, M. V. Aksenova, A. Nath, P. D. Ray, C. F.
Mactutus, and R. M. Booze, “Cocaine-mediated enhancement
of Tat toxicity in rat hippocampal cell cultures: the role of
oxidative stress and D1 dopamine receptor,” NeuroToxicology,
vol. 27, no. 2, pp. 217–228, 2006.
